

BioDADPep: A Bioinformatics database for anti diabetic peptides

Susanta Roy* & Robindra Teron

Department of Life Science and Bioinformatics, Assam University Diphu Campus, Diphu, Karbi Anglong 782 462, India; Susanta Roy - Email: susantoroy@gmail.com

Received October 19, 2019; Revised November 7, 2019; Accepted November 9, 2019; Published November 13, 2019

DOI: 10.6026/97320630015780

Abstract

The increasing number of cases for diabetes worldwide is a concern. Therefore, it is of interest to design therapeutic peptides to overcome side effects caused by the available drugs. It should be noted that data on several known anti-diabetic peptides is available in the literature in an organized manner. Hence, it is of interest to collect, glean and store such data in form of a searchable database supported by RDBMS. Data on anti-diabetic peptides and their related data are collected from the literature using manual search. Data on related peptides from other databases (THPdb, ADP3, LAMP, AHTPDB, AVPdb, BioPepDB, CancerPPD, CPPsite, DRAMP, SATPdb, CAMPR3 and MBPDB) are also included after adequate curation. Thus, we describe the development and utility of BioDADPep, a Bioinformatics database for anti-diabetic peptides. The database has cross-reference for antidiabetic peptides. The database is enabled with a web-based GUI using a simple Google-like search function. Data presented in BioDADPep finds application in the design of an effective anti-diabetic peptide.

Availability: <http://omicsbase.com/BioDADPep/>

Keywords: Diabetes mellitus (DM), therapeutic protein targets, anti-diabetic peptides, text mining, peptide database, cross reactivity

Background:

Diabetes mellitus is a pandemic non-communicable chronic autoimmune disease affecting the quality of life (diet and lifestyle). It is estimated that diabetes mellitus will rise to 592 million by the year 2035 [1]. Approximately 50% of patients with diabetes mellitus are believed to be unaware of their condition [2]. Diabetes Mellitus may go up from ninth to seventh most important reason of death worldwide by 2030 [3]. Based upon the etiology, diabetes mellitus can be divided into two main types, Type 1, "Juvenile Diabetes Mellitus" (Insulin Dependent Diabetes Mellitus) and Type 2, "adult type" (Non-Insulin Dependent Diabetes Mellitus) [4]. Type 1 diabetes (Insulin Dependent Diabetes Mellitus, IDDM or juvenile onset diabetes), occurs when the pancreas do not produce enough insulin due to destruction of pancreatic β -cells mediated by auto reactive T-cells resulting in chronic insulinitis [5].

In Type 2, "adult type" (Non-Insulin Dependent Diabetes Mellitus), primary insulin resistance, rather than defective insulin production due to β -cells destruction, seems to be the triggering alteration [6].

BioDADPep is an online database of published data about Type 1 and Type 2 diabetes mellitus peptides, their targets and other related data. A comprehensive visualization of all known antidiabetic peptides is important for peptide classification, modification and design. It is of interest to design different formulations of peptides for improved half-life, immunogenicity, chemical activity, solubility, side effects, toxicity and others [7]. It is promising to modify the structure to enhance stability, increase the half-life and improve membrane permeability of the peptide after calculating the binding and selectivity using structural features [8].

Several methods like truncations, PEGylation and cyclizations available to improve the properties and bioavailability using peptide mimetic design [8]. Bioactive peptides that help assess symptoms of diabetes are also included in the database [9].

Materials and Methods:

Database architecture and web interface




Figure 1: BioDADPep database Schema

Collection and organization of data

Primary data:

Peptides and related data were collected using literature search. We used PubMed to search for such peptides in research and review articles. Peptides were collected based on Type 1 and Type 2 diabetes annotations in literature. References are collected and stored in BioDADPep (Figure 1). This data forms primary data for the database. The source (synthetic or natural) of the peptides is also included in the database. Similar or linked or related peptides from other databases also included in the database.


Derived data:

Hydrophobicity, hydropathicity, hydrophilicity, charge, molecular weight and toxicity are derived from TOXINPRED [10]. Peptides in BioDADPep are compared with peptides in IEDB (Immune Epitope Database) [11] to extract antidiabetic peptides with cross reactivity features with anticancer, anti-inflammatory, anti-microbial, antioxidant, autoimmune and allergic. Such peptides in databases like THPdb [12], ADP3 [13]; LAMP [14]; AHTPDB [15]; AVPdb [16]; BioPepDB [17]; CancerPPD [18]; CPPsite [19]; DRAMP 2.0 [20]; SATPdb [21]; HIPdb [22]; CAMPR3 [23] and MBPDB [24] are also used for enrichment of the database.

Data retrieval search tool

User interface

All primary and derived data are included in BioDADPep in respective columns. The data related to a peptide can be browsed using the following parameters (i) accession number, (ii) peptide sequence, (iii) protein name, (iv) peptide length, (v) peptide source (start position - end position), (vi) protein function, (vii) *ptm, (viii) organism, (ix) mhc allele name, (x) mhc class, (xi) host mhc types present, (xii) ic50(µm), (xiii) assay_method/preclinical/clinical studies, (xiv) hydrophobicity, (xv) hydropathicity, (xvi) hydrophilicity, (xvii) charge, (xviii) molecular weight, (xix) toxin/non-toxin, (xx) peptides cross reactivity, (xxi) type 1 diabetes/type 2 diabetes (xxii) natural peptide/synthetic peptide and (xxii) references.



The screenshot shows the BioDADPep web interface. At the top, there are navigation links: Home, BioDADPep, Data Statistics, Acknowledgment, Help, and Contact. The main heading is 'BioDADPep'. Below it is a search bar with the label 'Search:'. A table displays search results with columns: Number, Peptide Sequence, Protein Name, Peptide Length, and Peptide Source (Start Position - End P). The table contains 10 rows of data. At the bottom, there are navigation arrows and a page number '255'.

Number	Peptide Sequence	Protein Name	Peptide Length	Peptide Source (Start Position - End P)
1	LYLVCGERV	Insulin	9	39-47
2	VYLKTNVFL	IGRP	9	206-214
3	LYLACERLL	ZnT8	9	158-166
4	SYNSVKEII	ZnT8	9	282-290
5	TYWCYITEL	DβH	9	233-241
6	NLAQDLATV	GFAP	9	143-151
7	SLEEEIRFL	GFAP	9	192-200
8	QLARQQVHV	GFAP	9	214-222
9	KIQVFLIVL	IAPP	9	5-13
10	FLIVLSVAL	IAPP	9	9-17

Figure 2: BioDADPep peptide search results.

Browsing:

BioDADPep interface has the following features

- (1) Home Page
- (2) BioDADPep Search
- (3) Data Statistics
- (4) Acknowledgment
- (5) Help
- (6) Contact

Home page:

Homepage give introduction on BioDADPep (Figure 2).

BioDADPep Search:

The BioDADPep database has search utility for keywords.

Data statistics:

Data statistics with graphs, figures and facts is made available.

Help:

The HELP page assists to navigate BioDADPep in a step-by-step manner.

Acknowledgement:

We are thankful to the Department of Life Science & Bioinformatics, Assam University – Diphu Campus, Diphu, Karbi Anglong 782 462, India for supporting us in every possible way.

We thank the list of all peptide databases used for the enrichment of BioDADPep. The open access charge for this article is largely sponsored by Biomedical Informatics (P) Ltd, India.

References:

- [1] Forouhi NG & Wareham NJ. *Medicine*. 2014 **42**:698 [PMID: 25568613]
- [2] Beagley J *et al.* *Diabetes Res Clin Pract*. 2014 **103**:150 [PMID: 24300018]
- [3] Shaw JE *et al.* *Diabetes Res Clin Pract*. 2010 **87**:4 [PMID: 19896746]
- [4] Patel DK *et al.* *Asian Pac J Trop Biomed*. 2012 **2**:411 [PMID: 23569941]
- [5] Atkinson MA & Eisenbarth GS. *Lancet*. 2001 **358**:221 [PMID: 11476858]
- [6] Pedicino D *et al.* *J Diabetes Res*. 2013 **2013**: 184258. [PMID: 23762872]
- [7] Mathur D *et al.* *Sci Rep*. 2016 **6**:36617 [PMID: 27819351]
- [8] Gruber CW *et al.* *Curr Pharm Des*. 2010 **16**:3071 [PMID: 20687879]
- [9] Xia EQ *et al.* *Mar Drugs*. 2017 **15**:E88 [PMID: 28333091]
- [10] Gupta S *et al.* *PLoS One*. 2013 **8**:e73957. [PMID: 24058508]
- [11] Vita R *et al.* *Nucleic Acids Res*. 2015 **43**:D405 [PMID: 25300482]
- [12] Usmani SS *et al.* *PLoS One*. 2017 **12**:e0181748 [PMID: 28759605]
- [13] Wang G *et al.* *Nucleic Acids Res*. 2016 **44**:D1087 [PMID: 26602694]
- [14] Zhao X *et al.* *PLoS One*. 2013 **8**:e66557. [PMID: 23825543]
- [15] Kumar R *et al.* *Nucleic Acids Res*. 2015 **43**:D956 [PMID: 25392419]
- [16] Qureshi A *et al.* *Nucleic Acids Res*. 2014 **42**:D1147 [PMID: 24285301]
- [17] Li Q *et al.* *Int J Food Sci Nutr*. 2018 **69**:963 [PMID: 29529902]
- [18] Tyagi A *et al.* *Nucleic Acids Res*. 2015 **43**:D837 [PMID: 25270878]
- [19] Gautam A *et al.* *Database* 2012 **2012**:bas015. [PMID: 22403286]
- [20] Kang X *et al.* *Sci Data*. 2019 **6**:148. [PMID: 31409791]
- [21] Singh S *et al.* *Nucleic Acids Res*. 2016 **44**:D1119 [PMID: 26527728]
- [22] Qureshi A *et al.* *PLoS One*. 2013 **8**:e54908. [PMID: 23359817]
- [23] Waghughu FH *et al.* *Nucleic Acids Res*. 2016 **44**:D1094 [PMID: 26467475]
- [24] Nielsen SD *et al.* *Food Chem*. 2017 **232**:673 [PMID: 28490127]


Edited by P Kanguane

Citation: Roy & Teron, *Bioinformation* 15(11): 780-783 (2019)

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

BIOINFORMATION

Discovery at the interface of physical and biological sciences



since 2005

BIOINFORMATION

Discovery at the interface of physical and biological sciences

indexed in

